These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 20950888)

  • 21. Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy.
    Kim YH; Goto K; Yoh K; Niho S; Ohmatsu H; Kubota K; Saijo N; Nishiwaki Y
    Cancer; 2008 Nov; 113(9):2518-23. PubMed ID: 18780323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term survival of a patient with small cell lung cancer after nine lines of chemotherapy and radiation.
    Gressner O; Popp H; Mey U; Friedrichs N; Strehl J; Sauerbruch T; Schmidt-Wolf IG; Gorschlüter M
    Onkologie; 2008 Sep; 31(8-9):469-72. PubMed ID: 18787355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
    Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R
    Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Morrissey LH; Scullin DC; Houston GA; Prasthofer EF; Gray JR; Burris HA; Greco FA
    Cancer; 2002 May; 94(9):2426-33. PubMed ID: 12033195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.
    Jotte R; Conkling P; Reynolds C; Galsky MD; Klein L; Fitzgibbons JF; McNally R; Renschler MF; Oliver JW
    J Clin Oncol; 2011 Jan; 29(3):287-93. PubMed ID: 21135284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cigarette burden (measured by the number of pack-years smoked) negatively impacts the response rate to platinum-based chemotherapy in lung cancer patients.
    Duarte RL; Luiz RR; Paschoal ME
    Lung Cancer; 2008 Aug; 61(2):244-54. PubMed ID: 18243408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Third-line chemotherapy in small-cell lung cancer: an international analysis.
    Simos D; Sajjady G; Sergi M; Liew MS; Califano R; Ho C; Leighl N; White S; Summers Y; Petrcich W; Wheatley-Price P
    Clin Lung Cancer; 2014 Mar; 15(2):110-8. PubMed ID: 24365050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.
    Lu C; Komaki R; Lee JS; Shin DM; Palmer JL; Coldman BJ; Pisters KM; Kurie JM; Fossella FV; Glisson BS
    Clin Cancer Res; 2003 Jun; 9(6):2085-91. PubMed ID: 12796372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy of adriamycin, etoposide plus ifosfamide on small cell lung cancer--a retrospective analysis of 69 cases treated in Centre Hospitalo-Universitaire de Bordeaux].
    Su Y
    Ai Zheng; 2006 Dec; 25(12):1569-72. PubMed ID: 17166389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
    Greco FA; Thompson DS; Morrissey LH; Erland JB; Burris HA; Spigel DR; Joseph G; Corso SW; Spremulli E; Hainsworth JD
    Oncologist; 2005 Oct; 10(9):728-33. PubMed ID: 16249353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer.
    Arúajo AM; Mendez JC; Coelho AL; Sousa B; Barata F; Figueiredo A; Amaro T; Azevedo I; Soares M
    Cancer Invest; 2009 May; 27(4):391-6. PubMed ID: 19266367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapy of small cell lung cancer with emphasis on oral topotecan.
    Pirker R; Berzinec P; Brincat S; Kasan P; Ostoros G; Pesek M; Plāte S; Purkalne G; Rooneem R; Skricková J; Stanculeanu D; Timcheva C; Tzekova V; Zakotnik B; Zielinski CC; Zwitter M
    Lung Cancer; 2010 Oct; 70(1):7-13. PubMed ID: 20576312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
    Némati F; Daniel C; Arvelo F; Legrier ME; Froget B; Livartowski A; Assayag F; Bourgeois Y; Poupon MF; Decaudin D
    Anticancer Drugs; 2010 Jan; 21(1):25-32. PubMed ID: 19823076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of topotecan and cisplatin in patients with small cell lung cancer.
    Ichinose Y; Seto T; Nishiwaki Y; Kiura K; Sakai H; Yokoyama A; Segawa Y; Ando M; Watanabe K
    Jpn J Clin Oncol; 2011 Feb; 41(2):197-203. PubMed ID: 20937601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network.
    Sallam M; Wong H; Escriu C
    BMC Pulm Med; 2019 Nov; 19(1):195. PubMed ID: 31675940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased metastasis and improved survival with early thoracic radiotherapy and prophylactic cranial irradiation in combined-modality treatment of limited-stage small cell lung cancer.
    Kamath SS; McCarley DL; Zlotecki RA
    Radiat Oncol Investig; 1998; 6(5):226-32. PubMed ID: 9822169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer.
    Quoix E; Breton JL; Gervais R; Wilson J; Schramel F; Cardenal F; Ross G; Preston A; Lymboura M; Mattson K
    Lung Cancer; 2005 Aug; 49(2):253-61. PubMed ID: 16022920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
    Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K;
    Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.
    Eckardt JR; von Pawel J; Papai Z; Tomova A; Tzekova V; Crofts TE; Brannon S; Wissel P; Ross G
    J Clin Oncol; 2006 May; 24(13):2044-51. PubMed ID: 16648504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.